Changes in depression symptom profile with gender-affirming hormone use in transgender persons 97 Table S3.2. Statistical models examining changes in total IDS-SR scores. The table displays the adjusted model, as reported in the main results, as well as models which adjust for age, cohort and cycle regulation use. The results display the estimated change in score, the 95% confidence interval and the p-values. Covariates Transmasculine (TM) group Transfeminine (TF) group Outcomes in total IDS-SR scores Age Study cohort (ENIGI vs. RESTED) Hormone use form 3 months vs. Baseline 12 months vs. Baseline 3 months vs. Baseline 12 months vs. Baseline Unadjusted model - - - -9.9%, (-20.7%; 2.3%) p=0.11 -10.3%, (-21.9%; 3.1%) p=0.13 12.6%, (-2.8%; 30.5%) p=0.12 15.8%, (-3.1%; 38.4%) p=0.11 Age-adjusted model 0.63% (0.04% to 1.24%) p=0.04 - - -9.9% (-20.7% to 2.3%) p=0.11 -11.2% (-22.8% to 2.0%) p=0.098 12.5% (-2.9% to 30.3%) p=0.12 15.1% (-3.8% to 37.4%) p=0.13 Cohort-adjusted model 0.71% (0.09% to 1.33%) p=0.027 -5.6% (-15.9% to 5.9%), p=0.33 - -9.8% (-20.6% to 2.5%) p=0.12 -11.2% (-22.8% to 2.0%) p=0.098 12.5% (-2.9% to 30.3%) p=0.12 15.1% (-3.8% to 37.4%) p=0.12 Cycle regulation use (use vs. no use) in TM participants 0.75% (-0.19% to 1.70%) p=0.13 - 10.2% (-8.3% to 32.7%) p=0.31 -8.9% (-20.0% to 3.8%) p=0.16 -10.1% (-22.1% to 3.8%) p=0.15 - - Testosterone form (gel vs. injections) in TM participants 0.74% (-0.21% to 1.70%) p=0.13 - -7.0% (-19.6% to 7.5%) p=0.33 -8.4% (-19.8% to 4.5%) p=0.19 -9.0% (-21.7% to 5.6%) p=0.22 - - Estrogen form (oral vs. transdermal) in TF participants 0.52% (-0.30% to 1.37%) p=0.23 5.5% (-11.7% to 26.1%) p=0.56 - - 11.6% (-3.9% to 29.6%) p=0.15 15.4% (-3.8% to 37.8%) p=0.12
RkJQdWJsaXNoZXIy MTk4NDMw